Effect of < em > P. corylifolia < /em > on the pharmacokinetic profile of tofacitinib and the underlying mechanism
Front Pharmacol. 2024 Apr 8;15:1351882. doi: 10.3389/fphar.2024.1351882. eCollection 2024.ABSTRACTThis work aimed to explore the mechanisms underlying the interaction of the active furanocoumarins in P. corylifolia on tofacitinib both in vivo and in vitro. The concentration of tofacitinib and its metabolite M8 was determined using UPLC-MS/MS. The peak area ratio of M8 to tofacitinib was calculated to compare the inhibitory ability of furanocoumarin contained in the traditional Chinese medicine P. corylifolia in rat liver microsomes (RLMs), human liver microsomes (HLMs) and recombinant human CYP3A4 (rCYP3A4). We found that ...
Source: Cancer Control - April 23, 2024 Category: Cancer & Oncology Authors: Yu Wang Quan Zhou Huihui Wang Wei Song Jianfeng Wang Abdullah Al Mamun Peiwu Geng Yunfang Zhou Shuanghu Wang Source Type: research
Molecules, Vol. 29, Pages 1915: Randomly Methylated & beta;-Cyclodextrin Inclusion Complex with Ketoconazole: Preparation, Characterization, and Improvement of Pharmacological Profiles
Molecules, Vol. 29, Pages 1915: Randomly Methylated β-Cyclodextrin Inclusion Complex with Ketoconazole: Preparation, Characterization, and Improvement of Pharmacological Profiles
Molecules doi: 10.3390/molecules29091915
Authors:
Yili Ding
Shufeng Xu
Charles Ding
Zhiyuan Zhang
Zhe Xu
As a powerful imidazole antifungal drug, ketoconazole&rsquo;s low solubility (0.017 mg/mL), together with its odor and irritation, limited its clinical applications. The inclusion complex of ketoconazole with randomly methylated &beta;-cyclodextrin was prepared by using an aqueous solution method after c...
Source: Molecules - April 23, 2024 Category: Chemistry Authors: Yili Ding Shufeng Xu Charles Ding Zhiyuan Zhang Zhe Xu Tags: Article Source Type: research
Longitudinal evaluation of the cutaneous and rectal microbiota of German shepherd dogs with perianal fistulas undergoing therapy with ciclosporin and ketoconazole
CONCLUSIONS AND CLINICAL RELEVANCE: Changes in lesional cutaneous and rectal microbiota occur in German shepherd dogs with perianal fistulas and shift over time with lesion resolution during immunomodulatory therapy. Further investigations of the role of cutaneous and enteric microbiota in the pathogenesis of perianal fistulas, and whether manipulation of microbial populations may ameliorate disease, are needed.PMID:38616572 | DOI:10.1111/vde.13249 (Source: Veterinary Dermatology)
Source: Veterinary Dermatology - April 15, 2024 Category: Veterinary Research Authors: Christine L Cain Ellen White Lindsey E Citron Qi Zheng Daniel O Morris Elizabeth A Grice Charles W Bradley Source Type: research
Longitudinal evaluation of the cutaneous and rectal microbiota of German shepherd dogs with perianal fistulas undergoing therapy with ciclosporin and ketoconazole
CONCLUSIONS AND CLINICAL RELEVANCE: Changes in lesional cutaneous and rectal microbiota occur in German shepherd dogs with perianal fistulas and shift over time with lesion resolution during immunomodulatory therapy. Further investigations of the role of cutaneous and enteric microbiota in the pathogenesis of perianal fistulas, and whether manipulation of microbial populations may ameliorate disease, are needed.PMID:38616572 | DOI:10.1111/vde.13249 (Source: Veterinary Dermatology)
Source: Veterinary Dermatology - April 15, 2024 Category: Veterinary Research Authors: Christine L Cain Ellen White Lindsey E Citron Qi Zheng Daniel O Morris Elizabeth A Grice Charles W Bradley Source Type: research
Longitudinal evaluation of the cutaneous and rectal microbiota of German shepherd dogs with perianal fistulas undergoing therapy with ciclosporin and ketoconazole
CONCLUSIONS AND CLINICAL RELEVANCE: Changes in lesional cutaneous and rectal microbiota occur in German shepherd dogs with perianal fistulas and shift over time with lesion resolution during immunomodulatory therapy. Further investigations of the role of cutaneous and enteric microbiota in the pathogenesis of perianal fistulas, and whether manipulation of microbial populations may ameliorate disease, are needed.PMID:38616572 | DOI:10.1111/vde.13249 (Source: Veterinary Dermatology)
Source: Veterinary Dermatology - April 15, 2024 Category: Veterinary Research Authors: Christine L Cain Ellen White Lindsey E Citron Qi Zheng Daniel O Morris Elizabeth A Grice Charles W Bradley Source Type: research
Longitudinal evaluation of the cutaneous and rectal microbiota of German shepherd dogs with perianal fistulas undergoing therapy with ciclosporin and ketoconazole
CONCLUSIONS AND CLINICAL RELEVANCE: Changes in lesional cutaneous and rectal microbiota occur in German shepherd dogs with perianal fistulas and shift over time with lesion resolution during immunomodulatory therapy. Further investigations of the role of cutaneous and enteric microbiota in the pathogenesis of perianal fistulas, and whether manipulation of microbial populations may ameliorate disease, are needed.PMID:38616572 | DOI:10.1111/vde.13249 (Source: Veterinary Dermatology)
Source: Veterinary Dermatology - April 15, 2024 Category: Veterinary Research Authors: Christine L Cain Ellen White Lindsey E Citron Qi Zheng Daniel O Morris Elizabeth A Grice Charles W Bradley Source Type: research
Cabergoline/Ketoconazole/Octreotide
(Source: Reactions Weekly)
Source: Reactions Weekly - April 1, 2024 Category: Drugs & Pharmacology Source Type: research
Effects of Clarithromycin and Ketoconazole on FK506 Metabolism in Different CYP3A4 Genotype Recombinant Metabolic Enzyme Systems
CONCLUSION: Compared with CYP3A4*1, CYP3A4*18 has a greater metabolism of FK506, clarithromycin and ketoconazole can inhibit both the enzymatic activities of CYP3A4*1 and CYP3A4*18, consequently affecting the metabolism of FK506 and the inhibitory on CYP3A4*1 is stronger.PMID:38523538 | DOI:10.2174/0113892002286019240315052145 (Source: Current Drug Metabolism)
Source: Current Drug Metabolism - March 25, 2024 Category: Drugs & Pharmacology Authors: Jinhua Wen Yuwei Xiao Menghua Zhao Chen Yang Weiqiang Hu Source Type: research
Effects of Clarithromycin and Ketoconazole on FK506 Metabolism in Different CYP3A4 Genotype Recombinant Metabolic Enzyme Systems
CONCLUSION: Compared with CYP3A4*1, CYP3A4*18 has a greater metabolism of FK506, clarithromycin and ketoconazole can inhibit both the enzymatic activities of CYP3A4*1 and CYP3A4*18, consequently affecting the metabolism of FK506 and the inhibitory on CYP3A4*1 is stronger.PMID:38523538 | DOI:10.2174/0113892002286019240315052145 (Source: Current Drug Metabolism)
Source: Current Drug Metabolism - March 25, 2024 Category: Drugs & Pharmacology Authors: Jinhua Wen Yuwei Xiao Menghua Zhao Chen Yang Weiqiang Hu Source Type: research
Effects of Clarithromycin and Ketoconazole on FK506 Metabolism in Different CYP3A4 Genotype Recombinant Metabolic Enzyme Systems
CONCLUSION: Compared with CYP3A4*1, CYP3A4*18 has a greater metabolism of FK506, clarithromycin and ketoconazole can inhibit both the enzymatic activities of CYP3A4*1 and CYP3A4*18, consequently affecting the metabolism of FK506 and the inhibitory on CYP3A4*1 is stronger.PMID:38523538 | DOI:10.2174/0113892002286019240315052145 (Source: Current Drug Metabolism)
Source: Current Drug Metabolism - March 25, 2024 Category: Drugs & Pharmacology Authors: Jinhua Wen Yuwei Xiao Menghua Zhao Chen Yang Weiqiang Hu Source Type: research
Effects of Clarithromycin and Ketoconazole on FK506 Metabolism in Different CYP3A4 Genotype Recombinant Metabolic Enzyme Systems
CONCLUSION: Compared with CYP3A4*1, CYP3A4*18 has a greater metabolism of FK506, clarithromycin and ketoconazole can inhibit both the enzymatic activities of CYP3A4*1 and CYP3A4*18, consequently affecting the metabolism of FK506 and the inhibitory on CYP3A4*1 is stronger.PMID:38523538 | DOI:10.2174/0113892002286019240315052145 (Source: Current Drug Metabolism)
Source: Current Drug Metabolism - March 25, 2024 Category: Drugs & Pharmacology Authors: Jinhua Wen Yuwei Xiao Menghua Zhao Chen Yang Weiqiang Hu Source Type: research
Effects of Clarithromycin and Ketoconazole on FK506 Metabolism in Different CYP3A4 Genotype Recombinant Metabolic Enzyme Systems
CONCLUSION: Compared with CYP3A4*1, CYP3A4*18 has a greater metabolism of FK506, clarithromycin and ketoconazole can inhibit both the enzymatic activities of CYP3A4*1 and CYP3A4*18, consequently affecting the metabolism of FK506 and the inhibitory on CYP3A4*1 is stronger.PMID:38523538 | DOI:10.2174/0113892002286019240315052145 (Source: Current Drug Metabolism)
Source: Current Drug Metabolism - March 25, 2024 Category: Drugs & Pharmacology Authors: Jinhua Wen Yuwei Xiao Menghua Zhao Chen Yang Weiqiang Hu Source Type: research
Effects of Clarithromycin and Ketoconazole on FK506 Metabolism in Different CYP3A4 Genotype Recombinant Metabolic Enzyme Systems
CONCLUSION: Compared with CYP3A4*1, CYP3A4*18 has a greater metabolism of FK506, clarithromycin and ketoconazole can inhibit both the enzymatic activities of CYP3A4*1 and CYP3A4*18, consequently affecting the metabolism of FK506 and the inhibitory on CYP3A4*1 is stronger.PMID:38523538 | DOI:10.2174/0113892002286019240315052145 (Source: Current Drug Metabolism)
Source: Current Drug Metabolism - March 25, 2024 Category: Drugs & Pharmacology Authors: Jinhua Wen Yuwei Xiao Menghua Zhao Chen Yang Weiqiang Hu Source Type: research
Effects of Clarithromycin and Ketoconazole on FK506 Metabolism in Different CYP3A4 Genotype Recombinant Metabolic Enzyme Systems
CONCLUSION: Compared with CYP3A4*1, CYP3A4*18 has a greater metabolism of FK506, clarithromycin and ketoconazole can inhibit both the enzymatic activities of CYP3A4*1 and CYP3A4*18, consequently affecting the metabolism of FK506 and the inhibitory on CYP3A4*1 is stronger.PMID:38523538 | DOI:10.2174/0113892002286019240315052145 (Source: Current Drug Metabolism)
Source: Current Drug Metabolism - March 25, 2024 Category: Drugs & Pharmacology Authors: Jinhua Wen Yuwei Xiao Menghua Zhao Chen Yang Weiqiang Hu Source Type: research
Effects of Clarithromycin and Ketoconazole on FK506 Metabolism in Different CYP3A4 Genotype Recombinant Metabolic Enzyme Systems
CONCLUSION: Compared with CYP3A4*1, CYP3A4*18 has a greater metabolism of FK506, clarithromycin and ketoconazole can inhibit both the enzymatic activities of CYP3A4*1 and CYP3A4*18, consequently affecting the metabolism of FK506 and the inhibitory on CYP3A4*1 is stronger.PMID:38523538 | DOI:10.2174/0113892002286019240315052145 (Source: Current Drug Metabolism)
Source: Current Drug Metabolism - March 25, 2024 Category: Drugs & Pharmacology Authors: Jinhua Wen Yuwei Xiao Menghua Zhao Chen Yang Weiqiang Hu Source Type: research
